---
title: "CAFs与化疗耐药又双叒叕发了NC"
date: 2023-05-29T10:14:28Z
draft: ["false"]
tags: [
  "fetched",
  "生信人"
]
categories: ["Acdemic"]
---
CAFs与化疗耐药又双叒叕发了NC by 生信人
------
<div><section><section powered-by="xiumi.us"><p>癌症相关成纤维细胞<span>（CAF）是肿瘤微环境(TME)的核心成分</span>，其与癌细胞存在广泛的相互作用，并能够影响TME的其他成分。此外，<span>研究也发现CAFs与癌症的预后及耐药有关</span>，因此癌症相关成纤维细胞在肿瘤中的作用也越来越受到关注。今天小编就给大家分享一篇今年2月刚刚发表在<strong><span>Nature Communications (IF:17.694)</span></strong>杂志上，研究CAF中铂类药物累积与结直肠癌进展及耐药关联的文章。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="0.36813186813186816" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7HJ9noJtnQvGCpFZDLKTU0n9pAv6ZjHcrcBxJe5VlS9FWbtuyryBUMg/640?wx_fmt=png" data-w="910" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7HJ9noJtnQvGCpFZDLKTU0n9pAv6ZjHcrcBxJe5VlS9FWbtuyryBUMg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>癌症相关成纤维细胞中铂类药物的长期累积会促进结直肠癌进展和耐药</p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>研究背景</strong></p></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><p>目前铂类药物是应用最广泛的抗癌药物之一，由于铂类药物可以有效的根除癌细胞，因此接受化疗(CT)的癌症患者中有近百分之五十都会接受铂类药物治疗。然而，<span>治疗中一些肿瘤可能会产生耐药性使得很多患者不能从铂类化疗中获益，因此有必要对耐药进行深入研究</span>。</p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>文章摘要</strong></p></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><p><span>研究将元素成像应用于治疗后结直肠癌的CT生物分布映射中，并全面分析了基于奥沙利铂的CT对肿瘤微环境中遗传程序的影响。</span>结果研究发现在治疗停止后很长时间内大部分奥沙利铂会被CAFs保留。研究也发现CAFs中累积的CT药物会增强TGF-β的活性和癌症的侵袭性。此外，研究使用骨膜蛋白作为化疗活性的基质标志物，发现骨膜蛋白在结直肠癌分子亚型CMS4中上调，且在治疗应答的患者中高表达。</p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>文章的主要内容及结果</strong></p></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><p><strong>1. 铂类药物在耐药成纤维细胞中累积</strong></p></section><section powered-by="xiumi.us"><p><span>文章首先研究了CT对TME的直接影响。</span>研究观察到奥沙利铂治疗后CRC小鼠模型中的癌细胞丰度，血管密度及免疫细胞浸润都会降低，而CAFs的丰度保持不变(图1a)，这表明CAFs对奥沙利铂高度耐药。接下来，研究在多个细胞系中评估了奥沙利铂的细胞毒性，结果与体内研究一致，相比成纤维细胞，其他细胞对奥沙利铂高度敏感(图1b)。接下来研究观察到癌细胞未能存活至奥沙利铂治疗的第9天，不过约80%的成纤维细胞耐受到治疗后的12日(图1c)。此外，研究也观察到与CRC细胞相比，成纤维细胞对奥沙利铂的吸收更高，且在提取奥沙利铂很长时间后仍可检测到微量铂(图1d)。接着作者分析了铂类药物在CRC肿瘤中的生物分布模式，对晚期结直肠癌样本中的奥沙利铂进行检测，结果发现奥沙利铂主要保留在富含成纤维细胞的区域(图1e、f)，且在最后一个周期治疗845日后仍可检测出(图1f)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.4805583250249252" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7JgJNXWPPxyZO6hZZzMPM612DMH4biaz79T2YCmK212GqPicfZopTcwPg/640?wx_fmt=png" data-w="1003" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7JgJNXWPPxyZO6hZZzMPM612DMH4biaz79T2YCmK212GqPicfZopTcwPg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图1 铂在抗治疗的成纤维细胞内积累</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>2. 铂刺激的成纤维细胞能够促进CRC进展</strong></p></section><section powered-by="xiumi.us"><p><span>这一部分研究分析了保留奥沙利铂的成纤维细胞对癌症进展的影响</span>。研究首先将未处理及经过体外奥沙利铂处理的成纤维细胞接种到裸鼠体内，结果观察到与未处理细胞相比，奥沙利铂预激活成纤维细胞的疾病潜伏期显著降低(图2a)，且奥沙利铂预处理能够显著增强癌细胞对铂类药物的耐药性(图2b)。接下来研究通过对奥沙利铂激活细胞的转录组分析识别出激活成纤维细胞应答特征(aFib-RS)，并观察到高aFib-RS与较差临床结局相关(图2c，d)。研究也观察到aFib-RS在CRC亚型CMS4中显著上调，且具有显著预后价值(图2e，f)。接下来研究通过GSEA分析发现在CT治疗无应答(图2g)或CT治疗后复发(图2h)的患者中，aFib-RS水平显著上调。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.362037037037037" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7HYkPDyHfBo5ticZwyHEFsSUcGg3U1giaOcicFeerFTBTyiaaBga4RyNwHw/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7HYkPDyHfBo5ticZwyHEFsSUcGg3U1giaOcicFeerFTBTyiaaBga4RyNwHw/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图2 铂刺激的成纤维细胞促进CRC进展</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>3. 铂积累诱导TGF-β通路的自分泌激活</strong></p></section><section powered-by="xiumi.us"><p><span>这一部分作者对奥沙利铂在成纤维细胞中激活的分子通路进行了分析。</span>研究对培养的成纤维细胞进行GSEA分析发现其富集到与衰老相关的基因和衰老相关分泌表型((SASP-S；图3a)，且成纤维细胞中衰老相关标记物高表达(图3b)，奥沙利铂处理后衰老相关的β-半乳糖苷酶活性也增加(图3c)，此外SASP-S在复发和无应答患者中上调(图3d)。接下来，研究观察到CT后SASP因子TGF-β1的mRNA表达显著增加(图3e)，研究也在奥沙利铂处理后培养的成纤维细胞中检测到TGF-β1上调(图3f)。进一步作者也发现Fib-TBRS在经过奥沙利铂处理的细胞中显著富集，在对CT无应答的肿瘤中Fib-TBRS也显著上调(图3g-i)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.3194444444444444" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv72dnRvNJSaIlNl9vfAQmmVrKVBOzSw0mSBPf0tWuzVxvSNakKKoLjzg/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv72dnRvNJSaIlNl9vfAQmmVrKVBOzSw0mSBPf0tWuzVxvSNakKKoLjzg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图3 铂的吸收增加了成纤维细胞中TGF-β的活性</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>4. 铂类药物诱导结直肠癌成纤维细胞的促癌分泌表型</strong></p></section><section powered-by="xiumi.us"><p><span>这一部分研究对铂类药物与结直肠癌成纤维细胞的表型关联进行了分析。</span>作者首先观察到白细胞介素11 (IL-11)的表达与aFib-RS水平显著相关(图4a)，在给予奥沙利铂后IL-11表达上调并随时间维持，且在施用TGF-β通路抑制剂后降低(图4b-e)。此外，研究也发现高IL11A表达是不良预后的独立预测因素并在CMS4肿瘤中显著上调(图4f，g)，研究也观察到IL11的表达增加能够用来推断复发患者(图4h)。研究也观察到CRC中IL11应答特征(CRC-IL11RS)在对治疗无应答或治疗后复发的患者中上调(图4i)。研究也在小鼠模型中观察到IL11的分泌显著增加了肿瘤形成的频率，并缩短了疾病潜伏期(图4j)，而降低IL11的表达则会限制肿瘤启动的能力(图4k)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.3788300835654597" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7NrfT0IOf3F5cUzKwgibkicRu6HQKmmxS4jVNmLaK5pIzDnRJ4TYoQiauA/640?wx_fmt=png" data-w="1077" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7NrfT0IOf3F5cUzKwgibkicRu6HQKmmxS4jVNmLaK5pIzDnRJ4TYoQiauA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图4 铂刺激的成纤维细胞中TGF-β通路的激活可上调IL11的分泌</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>5. POSTN是奥沙利铂诱导TME中TGF-β活性的标志物</strong></p></section><section powered-by="xiumi.us"><p><span>这一部分作者对CT应答的其他生物标志物进行了分析。</span>研究首先对成纤维细胞中受奥沙利铂调控的基因进行分析，结果识别到一种促进CRC进展和转移的CAF特异性分泌因子，骨膜蛋白(POSTN)，这也是aFib-RS中上调最明显的基因之一(图5a)。作者观察到在给予奥沙利铂后POSTN的水平大幅上调(图5b-d)。此外，研究也观察到CRC患者中POSTN表达与aFib-RS、FibTBRS和TGF-B1相关(图5e)。接下来，研究对4例未经治疗的CRC患者切除的肿瘤样本进行了体外奥沙利铂单药治疗，免疫组化分析发现与来自同一患者未治疗的肿瘤样本相比，治疗后的肿瘤样本显示出POSTN聚集(图5f, g)，且在治疗方案中加入TGF-β通路抑制剂可在体外大幅降低POSTN的表达(图5f, g)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.3074074074074074" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7Mm4Zib8IiaHjCdLAQoRxicT1GxJEL3fQcdL6ibLXeP5P0IGGznLTLzXSmA/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7Mm4Zib8IiaHjCdLAQoRxicT1GxJEL3fQcdL6ibLXeP5P0IGGznLTLzXSmA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图5 POSTN是CAFs中铂诱导TGF-β活性的标记物</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>6. POSTN蛋白水平识别CMS4亚型和肿瘤治疗应答</strong></p></section><section powered-by="xiumi.us"><p><span>这一部分研究对POSTN蛋白的预后价值进行了分析。</span>研究首先通过染色分析发现CMS4肿瘤中POSTN的表达和丰度均显著增加(图6a，b)。此外，研究发现POSTN蛋白表达水平的升高与无病生存期(DFS)的降低显著相关(图6c)，而基质丰度不能显著预测复发风险(图6d)。进一步研究发现POSTN水平与肿瘤基质负荷相关(图6e，f)。此外，作者发现POSTN水平在治疗后总体上调(图6g)，且治疗无应答样本中POSTN的表达显著高于有应答的样本(图6g)。对CT前和CT后配对样本的分析表明，无应答肿瘤要么在CT前固有POSTN高水平表达，要么在CT后增POSTN的表达增加(图6g, h)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.4416342412451362" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7QRCXCLguia2w6wzqlrH4SDIaiaQgGtUuXx3sWtia3WX3XmfD82uibo6t8g/640?wx_fmt=png" data-w="1028" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7QRCXCLguia2w6wzqlrH4SDIaiaQgGtUuXx3sWtia3WX3XmfD82uibo6t8g/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图6 POSTN是化疗耐药的基质标志物</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>7. POSTN亚型4的高表达降低了CRC对治疗的敏感性</strong></p></section><section powered-by="xiumi.us"><p><span>最后一部分作者研究了POSTN对CRC耐药的贡献。</span>研究比较分析了8种具有不同表达模式的POSTN剪接变异体，结果发现POSTN亚型4(POSTNi4)是CT诱导后上调最多的变异(图7a)，奥沙利铂会增加POSTNi4的表达水平(图7b)，且在处理后随时间而维持(图7d)，而TGF-β通路抑制则会消除POSTNi4的上调(图7c)。接下来研究试图评估POSTNi4对癌症进展的贡献，研究首先对患者来源的类器官进行工程改造，使其自主产生这种分泌因子(图7e)，并接种到小鼠皮下，结果观察到POSTNi4的表达对肿瘤起始或肿瘤扩大均无影响。接下来，研究用奥沙利铂治疗荷瘤小鼠20天，结果观察到奥沙利铂治疗显著降低对照肿瘤的扩张(图7f)，相反POSTNi4富集肿瘤的生长速度不受治疗的影响(图7f)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.125" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7xx2y0PsB4WdbA4RcBIicUVszv0RqAJSez6xU3G2EW0wo370nlq1QtpA/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjW2tM7NiclywYOufyMgibwjv7xx2y0PsB4WdbA4RcBIicUVszv0RqAJSez6xU3G2EW0wo370nlq1QtpA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图7 铂诱导的肿瘤间质中POSTN亚型4的表达增强了对治疗的抵抗力</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p>到这里这篇文章的主要内容就介绍完了，<span>研究采用干湿结合的方法，研究了癌症相关成纤维细胞中铂类药物的长期累积对结直肠癌进展和耐药的影响。</span>文章逻辑清晰，内容丰富，有理有据，无论是研究方法还是思路都值得小伙伴们参考学习。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section powered-by="xiumi.us"><p><strong>往期热点 </strong><span><strong><span>（点击标题跳转）</span></strong></span></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>01</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>线粒体质量控制</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>02</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>孟德尔随机化</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>03</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>成纤维细胞（CAFs）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>04</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>单细胞空间转录组</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>05</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>肿瘤相关巨噬细胞（TAM）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>06</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>细胞死亡</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>07</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>耐药</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><img data-ratio="1" data-w="350" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjWwWGiaDk0Xyx95BOia7rAEcD7QdhkjQbLv5jr2yh96iayNGTox4LEW0DCUVJq2FcJfB4qSJKNBQ1gnA/640?wx_fmt=png" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjWwWGiaDk0Xyx95BOia7rAEcD7QdhkjQbLv5jr2yh96iayNGTox4LEW0DCUVJq2FcJfB4qSJKNBQ1gnA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><section><p>课题设计 | 组学测序 |生信分析</p><p>培训工具 | 热点互动 | 资源互换</p></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><span>图文排版｜CY</span></p><p>文章转载请联系 | 15510012760（微信）</p><p>广告商务合作 | 18501253903（微信）</p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.575" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CFTasMDn98Zmf0038iakSGNh8Xic5ibJhOqOMqpI2dWbQicuDJW0edC5OMw/640?wx_fmt=png" data-w="640" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CFTasMDn98Zmf0038iakSGNh8Xic5ibJhOqOMqpI2dWbQicuDJW0edC5OMw/640?wx_fmt=png"></section></section><p powered-by="xiumi.us"><br></p></section><p><mp-style-type data-value="10000"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/I1ySeiaH8lT9qxxKk6UjaA",target="_blank" rel="noopener noreferrer">原文链接</a>
